These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 35094841)

  • 41. A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors.
    Pavone G; Motta L; Martorana F; Motta G; Vigneri P
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.
    Lang Y; Chai Q; Tao W; Liao Y; Liu X; Wu B
    Breast; 2023 Apr; 68():173-180. PubMed ID: 36780838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan.
    Dong W; Shi J; Yuan T; Qi B; Yu J; Dai J; He L
    Eur J Med Chem; 2019 Apr; 167():583-593. PubMed ID: 30822636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.
    Michaleas S; Moreno Oliver A; Mueller-Berghaus J; Sarac SB; van der Elst ME; Müller-Egert S; Zander H; Enzmann H; Pignatti F
    ESMO Open; 2022 Jun; 7(3):100497. PubMed ID: 35642987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
    De Moura A; Loirat D; Vaillant S; Korbi S; Kiavue N; Bello Roufai D; Escalup L; Desmaris R; Vaflard P; Cottu P; Pierga JY; Bidard FC; Cabel L; Acramel A
    Breast Cancer; 2024 Jul; 31(4):572-580. PubMed ID: 38600429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
    Zeybek B; Manzano A; Bianchi A; Bonazzoli E; Bellone S; Buza N; Hui P; Lopez S; Perrone E; Manara P; Zammataro L; Altwerger G; Han C; Tymon-Rosario J; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin A
    Sci Rep; 2020 Jan; 10(1):973. PubMed ID: 31969666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
    Starodub AN; Ocean AJ; Shah MA; Guarino MJ; Picozzi VJ; Vahdat LT; Thomas SS; Govindan SV; Maliakal PP; Wegener WA; Hamburger SA; Sharkey RM; Goldenberg DM
    Clin Cancer Res; 2015 Sep; 21(17):3870-8. PubMed ID: 25944802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
    O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
    Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.
    Sathe AG; Singh I; Singh P; Diderichsen PM; Wang X; Chang P; Taqui A; Phan S; Girish S; Othman AA
    Clin Pharmacokinet; 2024 May; 63(5):669-681. PubMed ID: 38578394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer.
    Ozaki Y; Masuda J; Takano T
    N Engl J Med; 2019 Jun; 380(24):2382. PubMed ID: 31189048
    [No Abstract]   [Full Text] [Related]  

  • 51. Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply.
    Bardia A; Mayer IA; Kalinsky K
    N Engl J Med; 2019 Jun; 380(24):2382. PubMed ID: 31189049
    [No Abstract]   [Full Text] [Related]  

  • 52. Targeted Treatment of Triple-Negative Breast Cancer.
    Young JA; Tan AR
    Cancer J; 2021 Jan-Feb 01; 27(1):50-58. PubMed ID: 33475293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
    Cardillo TM; Zalath MB; Arrojo R; Sharkey RM; Govindan SV; Chang CH; Goldenberg DM
    Oncotarget; 2024 Feb; 15():144-158. PubMed ID: 38386805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
    Dri A; Arpino G; Bianchini G; Curigliano G; Danesi R; De Laurentiis M; Del Mastro L; Fabi A; Generali D; Gennari A; Guarneri V; Santini D; Simoncini E; Zamagni C; Puglisi F
    Cancer Treat Rev; 2024 Feb; 123():102672. PubMed ID: 38118302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sacituzumab govitecan: an antibody-drug conjugate.
    Sahota S; Vahdat LT
    Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sacituzumab govitecan improves OS in heavily pretreated patients.
    Sidaway P
    Nat Rev Clin Oncol; 2023 Nov; 20(11):734. PubMed ID: 37684406
    [No Abstract]   [Full Text] [Related]  

  • 57. ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib.
    Lambertini M; Punie K
    ESMO Open; 2021 Feb; 6(1):100018. PubMed ID: 33399081
    [No Abstract]   [Full Text] [Related]  

  • 58. UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.
    Wong MH; Jones VC; Yu W; Bosserman LD; Lavasani SM; Patel N; Sedrak MS; Stewart DB; Waisman JR; Yuan Y; Mortimer JE
    Cancer Med; 2024 Aug; 13(16):e70096. PubMed ID: 39157928
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
    Spring LM; Tolaney SM; Fell G; Bossuyt V; Abelman RO; Wu B; Maheswaran S; Trippa L; Comander A; Mulvey T; McLaughlin S; Ryan P; Ryan L; Abraham E; Rosenstock A; Garrido-Castro AC; Lynce F; Moy B; Isakoff SJ; Tung N; Mittendorf EA; Ellisen LW; Bardia A
    Ann Oncol; 2024 Mar; 35(3):293-301. PubMed ID: 38092228
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ADC Could Benefit Some with Breast Cancer.
    Cancer Discov; 2019 May; 9(5):570. PubMed ID: 30867160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.